We could run Various scenarios , but i would be working on current figures of production ( based on 350m. ) and assume a 20 c margin . Given this would be base case ( with zero upside ) one can buy with confidence 70m in earnings x by 20 PE as it is a growth stock and you have upside of approx 3.5. What I expect is the company will grow to much higher revenue , but along the way we will have debt and equity issued . So I expect a much bigger market cap , but the SP will not grow as much due to the need for debt and equity along the way . I think if things go to plan upside maybe be 3-5 times SP but market cap may increase by 7-8 times .
I expect to see a few more deals Ann and 1st or second quarter next year a CR with potentially some debt
The key is however they have enough work to support more than current maker cap - therefore every additional deal is a strong SP driver . All medical devices and pharma companies start somewhere - this is the beginning if a bigger company long term IMO
UNS Price at posting:
67.5¢ Sentiment: LT Buy Disclosure: Held
